Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Lucid Diagnostics Inc. specializes in the development of innovative medical devices, particularly in the field of diagnostic solutions for cancer detection. The company's flagship product, the EsoGuard test, is designed for the early detection of esophageal cancer, a significant health concern in the U.S. and globally. Lucid's unique position lies in its proprietary technology and the growing demand for non-invasive diagnostic tests.
Lucid Diagnostics generates revenue primarily through the sale of its EsoGuard test, which is marketed to healthcare providers and institutions. The company benefits from a strong pricing power due to the test's unique technology and the increasing prevalence of esophageal cancer, which drives demand for early detection solutions.
Regulatory approvals for new diagnostic tests
Partnerships with healthcare providers and institutions
Market penetration rates of EsoGuard in the U.S. and internationally
Advancements in clinical data supporting the efficacy of EsoGuard
Regulatory changes affecting medical device approvals
Technological disruption from competing diagnostic solutions
Emergence of alternative cancer detection technologies
Pricing pressures from larger competitors with established products
High debt levels relative to market cap and revenue
Negative cash flow impacting liquidity
moderate - The demand for diagnostic tests can be influenced by overall healthcare spending, which is correlated with GDP growth.
Rising interest rates could increase financing costs for Lucid Diagnostics, impacting its ability to fund R&D and operational expenses, which may lead to a compression of valuation multiples.
minimal - The company has a high debt-to-equity ratio, but its operational model does not heavily rely on credit.
growth - Investors are likely attracted due to the potential for significant revenue growth from innovative diagnostic solutions.
high - The stock has shown significant price fluctuations, evidenced by a 28.5% decline over the last three months.